Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicOTC:CGIX
Date6/2013
Raised$15M
Post IPO Valuation

General Information

Websitecancergenetics.com
Twitter@Cancer_Genetics
CategoryBioTech
Phone201-528-9200
Emailcontact@cancergen...
Employees50
Founded1999
DescriptionCancer Diagnostic/Personalized Treatment

Offices

Cancer Genetics, Inc.
201 Route 17 North, 2nd Floor
Meadows Office Complex
Rutherford, NJ, 07070
USA
Cancer Genetics, Italia
Via San Vito n. 6
Milano, 20123, ITA

Funding

TOTAL $6.62M
FUNDING TOTAL $6.62M
Partial Close, 11/2010
$6.62M

Tags

Cancer Genetics

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual.

Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited, In addition we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, CGI’s scientific advisory board includes leading specialists in clinical cytogenetics, as well as significant thought leaders capable of driving adoption in the tri-state area. The company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.

CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership.

CGI’s dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests.

CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.

Recent Milestones

  • Stock
    Went public with stock symbol OTC:CGIX. (6/6/13)
    Posted 6/6/13 at 11:02pm
  • Check
    Cancer Genetics — Launch of DLBCL Complete Program. (1/1/13)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — Expansion of CLL Complete testing; SF3B1 mutation added. (1/1/13)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — MatBA-DLBCL CLIA & New York State approved for clinical use. (1/1/13)
    Posted 3/6/13 at 8:48am via cancergenetics.com
  • Check
    Cancer Genetics — UroGenRA-Kidney CLIA approved for clinical use. (1/1/13)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — MatBA-SLL CLIA and New York State approved for clinical use. (1/1/12)
    Posted 3/6/13 at 8:48am via cgimatba.com
  • Check
    Cancer Genetics — Expansion of Dx Lab services: - Solid tumor, ALK Break Apart FISH, BRAF & KRAS mutation analysis. - Expansion of CLL Complete testing; NOTCH1 & TP53 mutation added. (1/1/12)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — Expansion of Dx lab services: - JAK2 & MPL mutation analysis. - EGFR mutation analysis. (1/1/11)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — Launch of CLL Complete Program. (1/1/11)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — MatBA-CLL New York State licensed. (1/1/11)
    Posted 3/6/13 at 8:48am via cgimatba.com
  • Check
    Cancer Genetics — CGI establishes oncology-focused clinical trial services, Select One. (1/1/11)
    Posted 3/6/13 at 8:48am via cancergenetics.com
  • Dollar
    Cancer Genetics received $6.62M in Partial Close funding. (11/1/10)
    Posted 1/22/14 at 2:48am via sec.gov
  • Check
    Cancer Genetics — Summation Report is developed. (1/1/10)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — MatBA-CLL CLIA approved for clinical use. (1/1/10)
    Posted 3/6/13 at 8:48am via cgimatba.com
  • Check
    Cancer Genetics — CGI increases lab services. - Dx Laboratory: Cytogenetics, FISH, Molecular Genetics, Flow Cytometry, Histology, Immunochemistry. - R&D: DNA-FISH Probes, Array CGH. (1/1/09)
    Posted 3/6/13 at 8:48am
  • Check
    Cancer Genetics — CGI moves to Rutherford, New Jersey. (1/1/08)
    Posted 3/6/13 at 8:39am

Videos

Screenshots

Stock Price

Sources

  1. SEC (sec.gov) [edit]
  2. Citation Needed [add]
    Citation Needed [add]
    Citation Needed [add]
    Citation Needed [add]
    MatBA Accreditations (cgimatba.com) [edit]
    Citation Needed [add]
    Citation Needed [add]
    MatBA Accreditations (cgimatba.com) [edit]
    CGI Select One (cancergenetics.com) [edit]
    Citation Needed [add]
    MatBA Accreditations (cgimatba.com) [edit]
    Citation Needed [add]
    CGI Receives Regulatory Approvals for MatBA-DLBCL (cancergenetics.com) [edit]
    Citation Needed [add]
    Citation Needed [add]
    Citation Needed [add]
Edit This Page
Last Edited 1/22/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy